Results from two phase 3 trials—BRUIN CLL-313 and BRUIN CLL-314—indicate that pirtobrutinib is effective in frontline chronic lymphocytic leukemia. Released by Onclive, the findings suggest a promising option for patients who have not received prior treatment, though specific data remain behind a paywall.